Literature DB >> 16896281

B cell receptor signaling in human systemic lupus erythematosus.

Aimee E Pugh-Bernard1, John C Cambier.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to inform the scientific community of the most recent findings surrounding B cell receptor signaling function in human systemic lupus erythematosus and how altered B cell signaling may explain the characteristic hyperactivity of B cells in active disease and contribute to its pathogenesis. RECENT
FINDINGS: B cell receptor signaling is abnormal in patients with active systemic lupus erythematosus as demonstrated by increased calcium flux and global B cell hyperactivity. Altered signaling has been explained by a variety of factors such as defective FcgammaRIIB signaling, decreased expression of the protein tyrosine kinase Lyn, and increased serum levels of B lymphocyte stimulator.
SUMMARY: The studies reviewed suggest that B cells from systemic lupus erythematosus patients display molecular signaling defects that most likely contribute to pathogenesis of the disease and explain the characteristic hyperactivity of B cells in active disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16896281     DOI: 10.1097/01.bor.0000240353.99808.5f

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  13 in total

1.  PKK deficiency in B cells prevents lupus development in Sle lupus mice.

Authors:  D Oleksyn; J Zhao; A Vosoughi; J C Zhao; R Misra; A P Pentland; D Ryan; J Anolik; C Ritchlin; J Looney; A P Anandarajah; G Schwartz; L M Calvi; M Georger; C Mohan; I Sanz; L Chen
Journal:  Immunol Lett       Date:  2017-03-06       Impact factor: 3.685

2.  Oligomeric organization of the B-cell antigen receptor on resting cells.

Authors:  Jianying Yang; Michael Reth
Journal:  Nature       Date:  2010-09-05       Impact factor: 49.962

3.  Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis.

Authors:  Nam-Sihk Lee; Laura Barber; Shaw M Akula; George Sigounas; Yash P Kataria; Sergio Arce
Journal:  Clin Vaccine Immunol       Date:  2011-06-08

Review 4.  Systems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment.

Authors:  Andras Perl
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

5.  Development of ALS-like disease in SOD-1 mice deficient of B lymphocytes.

Authors:  Shulamit Naor; Zohar Keren; Tomer Bronshtein; Efrat Goren; Marcelle Machluf; Doron Melamed
Journal:  J Neurol       Date:  2009-03-12       Impact factor: 4.849

Review 6.  The role of mannose-binding lectin in systemic lupus erythematosus.

Authors:  Odirlei André Monticielo; Tamara Mucenic; Ricardo Machado Xavier; João Carlos Tavares Brenol; José Artur Bogo Chies
Journal:  Clin Rheumatol       Date:  2008-01-24       Impact factor: 2.980

Review 7.  Altered B cell receptor signaling in human systemic lupus erythematosus.

Authors:  Scott A Jenks; Iñaki Sanz
Journal:  Autoimmun Rev       Date:  2008-08-22       Impact factor: 9.754

Review 8.  T-cell and B-cell signaling biomarkers and treatment targets in lupus.

Authors:  Andras Perl; David R Fernandez; Tiffany Telarico; Edward Doherty; Lisa Francis; Paul E Phillips
Journal:  Curr Opin Rheumatol       Date:  2009-09       Impact factor: 5.006

9.  HS1, a Lyn kinase substrate, is abnormally expressed in B-chronic lymphocytic leukemia and correlates with response to fludarabine-based regimen.

Authors:  Federica Frezzato; Cristina Gattazzo; Veronica Martini; Valentina Trimarco; Antonella Teramo; Samuela Carraro; Anna Cabrelle; Elisa Ave; Monica Facco; Renato Zambello; Elena Tibaldi; Anna Maria Brunati; Gianpietro Semenzato; Livio Trentin
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

Review 10.  Antigen receptor signaling in the rheumatic diseases.

Authors:  Julie Zikherman; Arthur Weiss
Journal:  Arthritis Res Ther       Date:  2009-01-30       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.